PTC Therapeutics, Inc. Auditor
The independent registered public accounting firm that signed the audit report in each annual report on Form 10-K, newest first. PCAOB firm ID and the internal-control attestation are as tagged on the cover from fiscal 2021; earlier rows come from the signed report text.
- 2026-02-19: Fiscal year end 2025-12-31; Auditor Ernst & Young LLP; PCAOB firm ID 42; Location Iselin, New Jersey.
- 2025-02-27: Fiscal year end 2024-12-31; Auditor Ernst & Young LLP; PCAOB firm ID 42; Location Iselin, New Jersey.
- 2024-02-29: Fiscal year end 2023-12-31; Auditor Ernst & Young LLP; PCAOB firm ID 42; Location Iselin, New Jersey.
- 2023-03-08: Fiscal year end 2022-12-31; Auditor Ernst & Young LLP; PCAOB firm ID 42; Location Location Iselin, New Jersey.
| Filed | Fiscal year end | Auditor | PCAOB firm ID | Location | Internal-control attestation |
|---|
| 2026-02-19 | 2025-12-31 | Ernst & Young LLP | 42 | Iselin, New Jersey | Yes |
|---|
| 2025-02-27 | 2024-12-31 | Ernst & Young LLP | 42 | Iselin, New Jersey | Yes |
|---|
| 2024-02-29 | 2023-12-31 | Ernst & Young LLP | 42 | Iselin, New Jersey | Yes |
|---|
| 2023-03-08 | 2022-12-31 | Ernst & Young LLP | 42 | Location Iselin, New Jersey | Yes |
|---|
| 2023-02-21 | 2022-12-31 | Ernst & Young LLP | 42 | Iselin, New Jersey | Yes |
|---|
| 2022-02-22 | 2021-12-31 | Ernst & Young LLP | 42 | Iselin, New Jersey | Yes |
|---|
| 2021-02-25 | 2020-12-31 | Ernst & Young LLP | | Iselin, New Jersey | Yes |
|---|
| 2020-03-02 | 2019-12-31 | Ernst & Young LLP | | Iselin, New Jersey | |
|---|
| 2019-03-01 | 2018-12-31 | Ernst & Young LLP | | Iselin, New Jersey | |
|---|
| 2018-03-06 | 2017-12-31 | ERNST & YOUNG LLP | | Iselin, New Jersey | |
|---|
| 2017-03-16 | 2016-12-31 | ERNST & YOUNG LLP | | Iselin, New Jersey | |
|---|
| 2016-02-29 | 2015-12-31 | ERNST & YOUNG LLP | | | |
|---|
| 2015-03-02 | 2014-12-31 | ERNST & YOUNG LLP | | | |
|---|
| 2014-03-06 | 2013-12-31 | ERNST & YOUNG LLP | | | |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
|---|
| Veradermics, Inc (MANE) | United States | $4.839B | |
|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
|---|
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
|---|